课题基金 / 基金详情

Determinants of resistance in human schistosomiasis

Determinants of resistance in human schistosomiasis
人类血吸虫病耐药性的决定因素
批准号:
6694053
负责人:
DANIEL G COLLEY
金额:
$47.14万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-01-01 至 2007-12-31

项目摘要

项目成果

DANIEL G COLLEY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by the applicant): Infection with Schistosoma mansoni is a major health problem in much of Africa, the Middle East, and South America. Recent data show that based on time to reinfection, adults occupationally exposed to S. mansoni are resistant, develop resistance upon multiple treatments/re-infections, or remain susceptible. This proposal will test the hypothesis that resistance in these well-characterized Kenyans correlates with specific immune responses and genetic profiles, determine the dynamic immune changes accompanying resistance acquisition in these adults and school children, and see if immune changes can predict resistance. Based on preliminary data, treatment/reinfection studies, and animal models, resistance is proposed to correlate with both Thl and Th2 immune profiles, depending on the schistosome antigen-specific responses being studied. This hypothesis will be tested in well-characterized resistant and susceptible adults, and in those actively developing resistance due to multiple treatments/re-infections. Also, the antigen-specific immune profiles of children (usually susceptible to reinfection) will be determined as they respond to multiple treatments. The Specific Aims are: 1) Determine the antigen-specific cytokine and antibody isotype responses (immune profiles) that relate to the resistance or susceptibility of persons occupationally exposed to S. mansoni by flow cytometry, mRNA RT-PCR and gene activation micro-array analyses, in vitro culture for cytokine production and proliferation, and antibody ELISA analyses. 2) Determine the progression of immune profile changes during the actual development of resistance to S. mansoni in a prospectively followed cohort. 3) Determine if the progressive changes in immune profiles that are observed as adults become resistant to S. mansoni also occur longitudinally in multiply treated children in a highly endemic area. 4) Test the relationships of genetic polymorphisms likely to be associated with resistance or susceptibility to S. mansoni in well-characterized resistant or susceptible adults. Completion of these Specific Aims will: help establish the basis of resistance to schistosome infection that occurs upon multiple treatment/reinfection; provide both mechanistic insights into and correlates of resistance/susceptibility needed for future vaccine development against this debilitating disease; and determine if multiple mass treatment programs to control morbidity provide an added benefit by inducing a level of resistance to reinfection by S. mansoni.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Strengthening Biomedical Research Capacity in Kenya
  • 批准号:
    7616545
  • 项目类别:
  • 资助金额:
    $13.4万
  • 财政年份:
    2005
  • 负责人:
    DANIEL G COLLEY
  • 依托单位:
Strengthening Biomedical Research Capacity in Kenya
  • 批准号:
    7012147
  • 项目类别:
  • 资助金额:
    $14.81万
  • 财政年份:
    2005
  • 负责人:
    DANIEL G COLLEY
  • 依托单位:
Strengthening Biomedical Research Capacity in Kenya
  • 批准号:
    7112330
  • 项目类别:
  • 资助金额:
    $13.99万
  • 财政年份:
    2005
  • 负责人:
    DANIEL G COLLEY
  • 依托单位:
Malaria and Schistosomiasis Research Capacity in Kenya
  • 批准号:
    7216878
  • 项目类别:
  • 资助金额:
    $13.24万
  • 财政年份:
    2005
  • 负责人:
    DANIEL G COLLEY
  • 依托单位:
国内基金
海外基金
Naringin通过改善Leptin Resistance调节肠上皮AQP3重建糖脂代谢平衡的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    周烨
  • 依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
SMC5-NSMCE2功能异常激活APSCs中p53/p16衰老通路导致脂肪萎缩和胰岛素抵抗的机制研究
  • 批准号:
    82371873
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2023
  • 负责人:
    乔洁
  • 依托单位:
脂肪酸合成通过GDF15/IRS2介导胰岛素抵抗促进血管内皮细胞活化导致脓毒症肺损伤的机制研究
  • 批准号:
    82372203
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李然然
  • 依托单位: